• Fisheries and Aquatic Sciences
• /
• 제4권4호
• /
• pp.197-200
• /
• 2001

To investigate the re-treatment time of Microcotyle sebastis by oral administration of praziquantel, the residue levels of praziquantel in plasma of rockfish Sebastes schlegeli administered orally at a dose of 200 mg/kg B.W. were analyzed by reversed-phase HPLC, and the concentrations of praziquantel in the plasma were correlated with the extermination of M. sebastis. The absorption and depletion of praziquantel in the blood of rockfish were fast and the residual concentrations of praziquantel declined below $4\mu g/mL$ within 24 hr post treatment. Most of worms were exterminated within 3 hr after oral administration of praziquantel, however, a small number of M. sebastis were not killed by the treatment until end of the experiment. Considering fast drop of praziquantel in blood and extermination pattern of M. sebastis in the present results, retreatment at an interval of 9-12 hr would be effective for eradication of M. sebastis.

• 대한수의학회지
• /
• 제39권2호
• /
• pp.257-266
• /
• 1999

Ivermectin is a widely used broad spectrum antiparasitic agent in veterinary medicine. In this work, we examined the pharmacokinetic parameters and the tissue residue profile of a new injectable formulation of ivermectin developed for pigs. The plasma ivermectin levels reached the peak at about 9 and 2 hours after the administrations in young and adult pigs, respectively. But the elimination half-life (3-3.5 days) and the $C_{max}$ values (24~28 ng/ml) were not significantly different between young and adult pig groups. When compared to the reference formulation, the $C_{max}$ of test formulation was higher and $T_{1/2}$ values were shorter than those of the reference formulation, respectively. The tissue residue levels were dose- and time-dependent and were higher in the liver and fat, than in the other tissues such as the injection sites, the kidney, intestine, muscle, plasma (4~74 ng/g) at the 7th day after the administration of both formulations of ivermectin. Then, the mean tissue ivermectin levels at the 21st day after the administration in all the tissues decreased to 7.4 and 25% of the 7th day levels in the test and reference formulations, respectively. In general, the tissue levels of ivermectin in the animals treated with the test formulation decreased more rapidly than those with the reference formulation. The tissue to plasma distribution ratio (T/P ratio) of ivermectin was higher in the liver and fat than other tissues. The T/P ratio in the liver of animals treated with the test formulation was somewhat higher than that in the animals treated with the reference formulation. Taken together, the results of pharmacokinetic and tissue residue studies indicate that the test formulation of ivermectin for subcutaneous injection is comparable to the reference formulation, but unique in that it has higher peak plasma concentrations, shorter elimination half-life and higher T/P ratio in the liver than the reference formulation.

• Journal of Pharmaceutical Investigation
• /
• 제31권2호
• /
• pp.89-94
• /
• 2001

The pharmacokinetics of recombinant human granulocyte colony stimulating factor (rhG-CSF) following intravenous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) administration of HM1041l-lyo and HM10411-liq (lyophilized and liquid formulations of rhG-CSF, recently under development by Hanmi Pharmaceutical Company) were studied in rats, and compared with that of Filgrastim (conventional formulation of rhG-CSF on market). The plasma concentration of rhG-CSF was quantified using a specific ELISA. The pharmacokinetic parameters of rhG-CSF, after i.v., i.m. and s.c. administration of Filgrastim, HM1041l-lyo and HM1041l-liq to rats at a rhG-CSF dose of $10\;{\mu}g/kg$, were almost identical among the three formulations. No dose-dependency was observed in the pharmacokinetic parameters of rhG-CSF following i.v. administration in the dose range of $5{\sim}100\;{\mu}g/kg$. rhG-CSF, after i.v. administration of the three preparations at a dose of $10\;{\mu}g/kg$ to rats, was detected at low levels in all of the body tissues with highest tissue/plasma ratio of $0.46{\sim}0.51$ for the kidney at 30 min after the administration. The pharmacokinetics of rhG-CSF, after i.v. administration to mice at a dose of $10\;{\mu}g/kg$, were comparable among the three formulations. In conclusion, HM10411-lyo and HM10411-liq exhibited similar pharmacokinetics for rhG-CSF with Filgrastim regandless of animal species. Considering the fact that HM10411 series, contrary to Filgrastim, are proteins lacking a methionine residue, the methionine moiety in rhG-CSF molecule does not appear to influence the pharmacokinetics of the protein significantly.

• 한국어병학회지
• /
• 제28권1호
• /
• pp.43-51
• /
• 2015

아목시실린(AMOX)의 수온에 따른 약동학적 특성과 잔류량을 알아보기 위해 넙치(평균 100 g)를 $(17{\pm}2)^{\circ}C$ 및 $(22{\pm}2)^{\circ}C$에 수용하여 1회 근육투여한 후 시간에 따른 혈장, 간, 신장의 잔류농도를 HPLC-UVD로 분석하였다. 이 측정결과를 바탕으로 2-compartmental model로 PKSolver program을 이용하여 AMOX의 반감기, AUC 등의 pharmacokinetic parameter를 조사하였다. 혈장, 간, 신장의 최고농도 및 도달시간의 범위가 각각 $27.23-257.36{\mu}g/m{\ell}$ (0.05-0.91 h), $5.49-41.65{\mu}g/g$ (1.36-3.28 h), $16.75-129.31{\mu}g/g$ (1.95-4.49 h)으로 나타났다. 수온에 따른 잔류기간을 시험하기 위해 어체중 kg 당 40 및 400 mg을 투여한 후 LC-MS/MS로 분석하였다. 40 mg/kg은 5일 후, 400 mg/kg은 7일 후에 각각 최대잔류허용량인 0.05 mg/kg 이하로 검출되었다.

• 한국어병학회지
• /
• 제35권1호
• /
• pp.93-102
• /
• 2022

본 연구에서는 뱀장어에 대한 trichlorfon (TCF)의 잔류허용기준(maximum residue level, MRL) 설정을 위한 기초 자료를 얻기 위하여 뱀장어를 대상으로 하여 trichlorfon (TCF) 노출에 따른 체내 잔류량 및 약물동태학적 분석을 실시했다. 28℃와 18℃ 에서 각각 30 ppm 및 150 ppm의 TCF를 30분간 약욕하여 이에 따른 체내 약물잔류농도를 LC-MS/MS로 분석한 결과를 바탕으로 PK solver program 을 이용하여 혈청, 근육 및 간에서 TCF의 약동학 파라미터를 얻었다. 혈청, 근육 및 간에서 최고 농도(C_max)는 25.87-357.42, 129.91-1043.73 및 40.47-375.20였고, 최고 농도 도달시간(T_max)는 0.13-1.32 h, 1.17-3.34 h, 및 0.14-5.40 h이었으며, 배설 반감기 (T_1/2)는 2.13-3.92 h, 5.30-10.35 h, 및 0.65-13.81 h이었다. 30 mg/L농도 투여군에서는 약욕 후 96시간이 지난 뱀장어의 혈청에서 TCF가 검출되지 않았으며, 근육 및 간에서는 336시간이후 부터 검출 한계 이하로 나타났다. 반면에 150 mg/L농도 투여군에서는 약욕 후 336시간이 지난 뱀장어의 혈청에서 TCF가 검출되지 않았지만, 근육 및 간에서는 336시간에도 검출되었다. 결론적으로 본 연구를 통해 얻은 결과들은 향후 양식 뱀장어에 대한 trichlorfon (TCF)의 잔류허용기준(MRL) 설정에 유용한 기초 자료로 활용 될 것으로 기대한다.

• 한국임상약학회지
• /
• 제15권1호
• /
• pp.46-49
• /
• 2005

A simple HPLC method was employed for the determination of pentoxifylline in human serum. After addition of internal standard (IS, 50 uL of 3 ug/mL chloramphenicol methanol solution) into the serum sample, the drug and IS were extracted by dichloromethane. Following a 1-min vortex-mixing and a 15-min centrifugation at 3500 게m, the organic phase was transferred and evaporated to dryness under a vacuum. The residue was reconstituted with 120 ${\mu}L$ of mobile phase and 50 ${\mu}L$ was injected into C18 column with a mobile phase composed of 0.034 M phosphoric acid adjusted to pH 4 with 10 M NaOH and acetonitrile (75:25, v/v). The samples were detected using an ultraviolet detector at 273 nm. The method was simple, specific and validated with a limit of 10 ng/mL. Intra- and inter-day precision and accuracy were acceptable for all quality control samples including the lower limit of quantification. The applicability of this method was evaluated by analysis of human serum after oral administration of a single 400 mg dose to 8 healthy subjects. The pharmacokinetic parameters for pentoxifylline in human subjects were calculated using WinNonlin program. As a result, $AUC_{t},\;C_{max},\;T_{max}$ and $t_{1/2}$ were $962.28{\pm}645.69\;ng{\cdot}/mL$, $132.82{\pm}42.05$ ng/mL, $2.06{\pm}2.68$ hr and $8.74{\pm}4.38$ hr, respectively. Based on the results, this validated method appears to be useful fur the pharmnacokinetic study of pentoxifylline in humans.

• Fisheries and Aquatic Sciences
• /
• 제23권4호
• /
• pp.10.1-10.10
• /
• 2020

Background: Butaphosphan (BTP) has recently been introduced into the Korean aquaculture sector as a stressattenuating agent. In this study, a sensitive chemical analytical method was established for the detection of BTP in the olive flounder (Paralichthys olivaceus) tissues. Methods: Utilizing a method employing liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), detection sensitivity, specificity, and precision were satisfactorily established. Temporal changes in the BTP plasma and muscle concentrations were assessed after a single intramuscular injection of BTP (50 and 150 mg/kg) to the olive flounder maintained at 13 ℃ or 22 ℃. Results: High BTP plasma levels were achieved immediately after the injection, and the drug was rapidly eliminated. Additionally, plasma BTP levels were markedly dependent on the elimination rate, which, in turn, seemed dependent on the water temperature, with the drug elimination half-life and mean residence time significantly shorter at 22 ℃ than 13 ℃. Overall, muscle BTP levels were markedly lower than the plasma levels. Notably, muscle levels were not influenced by water temperatures. Muscle BTP concentrations were used to estimate the necessary withdrawal period for drugs used in food fish, with BTP levels maintained far below the possible hazardous limit. Conclusions: In conclusion, the established LC-MS/MS method can be used for BTP residue detection with high sensitivity and reproducibility.

• Applied Biological Chemistry
• /
• 제40권2호
• /
• pp.157-162
• /
• 1997

Cephem계 항생물질의 기본 구조인 7-aminocephalosporanic acid (7-ACA)의 $C_3$ 위치에 thiol기를 도입하고 $C_7$ 위치 aminothiazole기를 결합시킨 신규 화합물(YH-487)에 대한 감염치료효과, 체내동태 그리고 이의 투여에 의한 흰쥐의 장내균총들의 영향에 관하여 검토한 결과, YH-487을 흰쥐에 꼬리정맥을 통하여 20mg/kg으로 투여시 혈중 최고농도 등 체내동태는 제 3세대 ${\beta}-lactam$계 약물인 cefotaxime 등과 유사한 결과를 보였으며 장기조직으로의 이행성은 신장으로의 이행율이 가장 좋았고 배설은 신장 배설 타입이었으며 배설된 약물은 체내의 대사에 의한 변화를 받지 않았다. 또한 YH-487의 대장균 감염증에 대한 치료효과는 cefotaxlme의 3배, cefotiam의 약 20배 정도 높았다. 한편 YH-487의 투여에 의한 흰쥐의 장내 균총의 변화는 Enterobacter와 Bacteroides속 등 Gram 음성 세균은 투여 후 균수가 크게 감소 하였으나 Lactobacillus, Bifidobacterium과 Staphylococcus속 등 Gram 양성 세균은 영향을 받지 않았다. 또한 YH-487을 연속 투여한 후 분리한 균주의 항균활성은 투여전의 균주와 차이가 없어 내성균의 출현 가능성이 낮았다.

• Journal of Pharmaceutical Investigation
• /
• 제35권2호
• /
• pp.123-127
• /
• 2005

An HPLC method was employed for the determination of ethambutol in human plasma. After addition of internal standard (IS, octylamine, $2\;{\mu}g/mL$) and alkalinization of the plasma with 5 M sodium hydroxide, the drug and IS were extracted into the mixture of chloroform and diethyl ether (40:60, v/v). Following a 15-min vortex-mixing and a 10min centrifugation, the organic phase was spiked with $100{\mu}L$ of phenylethylisocyanate $(2000{\mu}g/mL)$ for chemical derivatization, mixed for 5 min and evaporated to dryness under a stream of nitrogen. The residue was reconstituted with $100{\mu}L$ of mobile phase and $20{\mu}L$ was injected into C18 column with a mobile phase consisting of methanol:water (70:30, v/v). The samples were detected utilizing an ultraviolet detector at 200 nm. The method was specific and validated with a limit of $0.15\;{\mu}g/mL$. Intra- and inter-day precision and accuracy were acceptable for all quality control samples including the lower limit of quantification. The applicability of this method was demonstrated by analysis of human plasma after oral administration of a single 1200-mg dose to 20 healthy subjects. From the plasma ethambutol concentration vs. time curves, the mean AUC was $9.61{\pm}1.64\;{\mu}g{\cdot}hr/mL$ and Cmax of $2.68\;{\mu}g/mL$ reached 2.73 hr after administration. The mean biological half-life of ethambutol was $3.46{\pm}1.21$ hr. Based on the results, this simple and validated assay could readily be used in any pharmacokinetic studies using humans.

• Biomolecules & Therapeutics
• /
• 제5권1호
• /
• pp.53-58
• /
• 1997

$[Lys^7$]dermorphin, abbreviated K7DA, which has structural features similar to a metabolically stable $\mu$-opioid peptide agonist $[D-Arg^2, Lys^4$]dermorphin analogue (DALDA), but is intrinsically more potent with respect to binding to the $\mu$-opioid peptide receptor. The present studies report on attempts to enhance brain uptake of systemically administered K7DA by conjugation to a complex of streptavidin (SA) and the OX26 murine monoclonal antibody to the rat transferrin receptor, which undergoes receptor-mediated transcytosis through the blood-brain barrier (BBB). SA-OX26 conjugate mediates BBB transport of biotinylated therapeutics. The K7DA is monobiotinylated at the $\varepsilon$-amino group of the $[Lys^7$] residue with cleavable linker using NHS-SS-biotin. The brain uptake of $^{125}I$ labeled biotinylated K7DA ($^{125}I$-bio-SSa-K7DA) was very small and rapidly metabolized after intravenous injection. The brain uptake, expressed as percent of injected dose delivered per gram of brain, of the $^{125}I$-bio-55-K7DA bound to the SA-OX26 conjugate $^{125}I$-bio-SS-K7DA/SA-OX26) was 0.14$\pm$0.01, a level that is 2-fold greater than the brain uptake of morphine. The cleavability of the disulfide linker in vivo in rat plasma and brain was assessed with gel filtration HPLC and intravenous injection of labeled opioid chimeric peptides. The disulfide linker is stable in plasma in vivo but is cleaved in rat brain in vivo. In conclusion, these studies show that delivery of these potential opioid peptides to the brain may be improved by coupling them to vector-mediated BBB drug delivery system.